The current measles outbreak has gripped US states like Texas and New Mexico leaving people worried whether it would become a new pandemic. According to the Texas Department of State Health Services as of February 21, 90 cases were diagnosed in the last month in the South Plains area, with at least 77 of them were reported in children and teens under 17.

Measles is highly contagious and can be deadly. The outbreak, which started spreading in late January, has resulted in multiple hospitalizations, with at least nine confirmed cases and three probable cases as of early February. Health officials caution that at least one in five infected individuals will have to be hospitalized, highlighting the severity of the situation.

Misinformation surrounding vaccines and with the new Trump administration anti-vaccine campaigs, has causing parents to hesitate or refuse vaccination.

Furthermore, the country down under Australia is also witnessing a surge in measles cases as health officials in Sydney have issued an urgent alert, urging residents to watch for measles symptoms after an infected individual visited several places in Sydney over the last seven days.

Authorities report that the traveller had returned from South East Asia where there are ongoing outbreaks of measles.

What Are The Symptoms Measles?

Key symptoms of measles include fever, a runny nose, sore eyes, and a cough. Typically, a red, blotchy rash appears three to four days later, spreading from the head down to the body. Symptoms can manifest between 7 and 18 days after exposure.

Anyone who experiences these symptoms after potential exposure should immediately contact their doctor or emergency department. It is crucial to call ahead before visiting to avoid potentially exposing others in the waiting room. Dr. Selvey also highlighted that ongoing measles outbreaks are occurring in various parts of the world, making awareness and prompt action essential.

Why It Is Important To Get Vaccinated?

According to CDC everyone should get the MMR vaccine. It protects you from measles, mumps, and rubella. Getting vaccinated helps stop these diseases from spreading. There are two safe MMR vaccines available. They work the same way, so it doesn't matter which one you get. Kids can also get a shot that protects against chickenpox too, but this is only for children.

Who Should Get Vaccinated?

Kids Need Two Shots

All children should get two MMR shots. The first shot should be given when they are between 12 and 15 months old. The second shot should be given when they are between 4 and 6 years old. If needed, the second shot can be given earlier, but it must be at least 28 days after the first shot.

College Students Need to Be Protected

Students going to college or other schools after high school, need two shots if they are not already immune. The shots must be at least 28 days apart.

Adults Need at Least One Shot

Most adults need at least one MMR shot. Some adults need two shots, especially those who work in healthcare, travel a lot, or go to college. These people should get two shots, with 28 days between them.

Travelers Need to Be Extra Careful

Anyone traveling to other countries should make sure they are protected. Babies 6 to 11 months old should get one shot before traveling. Kids 12 months and older, teens, and adults need two shots, with 28 days between them.

Healthcare Workers Must Be Immune

People who work in healthcare should have proof that they are immune to measles, mumps, and rubella. If they are not immune, they need two MMR shots, spaced 28 days apart.

Women Thinking About Having Babies

Women who might get pregnant should talk to their doctor about the MMR vaccine. It's safe to get the shot while breastfeeding.

The weight loss drug competition has gotten more serious as a late-stage clinical trial compared two next generation obesity drugs and found Eli Lilly's Zepbound to produce greater result in weight loss than Novo Nordisk's much-anticipated CargiSema. The new Novo Nordisk drug was once projected to redefine the treatment landscape.

As a result, Novo Nordisk's shares have dropped by 16 per cent. However, the outcome is not just significant because of market reaction, but also because these medicines are now shaping how doctors treat obesity, a chronic disease affecting more than one billion people worldwide. The results suggest the next phase of weight-loss therapy will be decided less by hype and more by real world effectiveness.

Zepbound Outperforms Other Weight Loss Drugs: What Did The Comparison Reveal?

In the head-to-head study, patients taking CagriSema lost an average of 23 per cent of their body weight after 84 weeks. Participants treated with tirzepatide, sold as Zepbound for obesity and Mounjaro for type 2 diabetes, lost 25.5 per cent.

The gap may appear small but in clinical medicine it matters. The trial’s primary goal was to prove the new Novo Nordisk therapy was at least not inferior to tirzepatide. It failed to meet that benchmark.

Earlier trials had suggested CagriSema might rival or even surpass existing GLP-1 based drugs. However, those studies did not directly compare the medicines against each other. This time the comparison was unavoidable.

Zepbound Outperforms: Why These Drugs Matter Beyond Weight Loss

Modern anti-obesity medicines do more than reduce body fat. Doctors increasingly prescribe them to lower the risk of heart disease, diabetes complications, sleep apnea and fatty liver disease.

Zepbound belongs to a newer class of dual-action hormone therapies. It mimics both GLP-1 and GIP hormones, which regulate appetite, insulin response and metabolism.

CagriSema uses a different strategy. It combines semaglutide, the active ingredient behind earlier blockbuster treatments, with an experimental molecule called cagrilintide that targets hunger signals from another pathway.

Researchers hoped attacking appetite through multiple mechanisms would produce stronger results. The trial showed improvement but not enough to surpass tirzepatide.

Zepbound Outperforms Other Weight Loss Drugs: Did The Trial Design Effect The Outcome?

Novo Nordisk executives said the study’s open label design may have influenced results. Participants knew which drug they were receiving, which could lead to behavioral bias.

Doctors often see adherence improve when patients believe they are taking a proven therapy rather than an experimental one. The company suggested familiarity with tirzepatide may have worked in its favor.

Still, clinical researchers generally consider head-to-head trials the most reliable way to evaluate competing treatments. Even accounting for bias, the data indicates tirzepatide currently delivers slightly greater sustained weight reduction.

Zepbound Outperforms Other Weight Loss Drugs: What Does This Mean For Obesity Treatment Race?

The study highlights a shift happening in obesity care. The first generation of GLP-1 drugs proved weight loss medications could achieve double digit body weight reduction. Now companies are competing over incremental but clinically meaningful gains.

For patients, even a two to three percent difference can affect blood sugar control, blood pressure and long term cardiovascular risk. It can also influence insurance coverage decisions and treatment guidelines.

Novo Nordisk still plans to bring CagriSema to market and has filed for regulatory approval, with a decision expected by late 2026. The company is also studying higher doses and alternative dosing strategies to maximize effectiveness.

Prime Minister Narendra Modi, in his latest episode of Mann Ki Baat, highlighted the growing awareness of organ donations in India.

The Prime Minister lauded people who have undertaken such noble deeds.

According to the latest data from the Ministry of Health and Family Welfare, India has recorded a fourfold surge in organ transplants over the last decade. From less than five thousand in 2013, organ transplants in the country jumped to nearly 20 thousand in 2025.

“Awareness about organ donation is steadily rising in India these days. This is helping those who are in need of it. It is also strengthening medical research in the country. Many organizations and individuals are doing extraordinary work in this direction,” the PM said in the 131st episode of the monthly radio program.

The Prime Minister also paid tributes to 10-month-old Aalin Sherin Abraham, from Kerala, who lost her life in an accident but gave life to five people to become the youngest organ donor in the state.

“There is no greater sorrow for any parent than losing one’s own child. The pain of losing a very young child is deeper. Just a few days ago, we lost Aalin Sherin Abraham, a little innocent girl from Kerala. She left this world at the age of just 10 months.

PM Modi said even amidst "profound pain", Aalin's father, Arun Abraham, and mother, Sherin, decided to donate her organs.

"While on the one hand, they grieved the loss of their daughter, on the other, they were also filled with a spirit of helping others," PM Modi said.

“Aalin Sherin Abraham is no longer with us, but her name has joined the ranks of the nation's youngest organ donors,” he added.

He also mentioned the names of organ recipients -- Lakshmi Devi from Delhi, Gaurang Banerjee from West Bengal, and Ramdev Singh of Sikar, Rajasthan -- who, after receiving the transplants, got a second chance at life.

“You will come across many such inspiring examples. This proves once again that a single noble act can change the lives of countless people. I heartily commend all those who have undertaken such noble deeds,” the Prime Minister said.

Where Does India Stand In Terms Of Organ Transplants?

The National Organ and Tissue Transplant Organization (NOTTO) has recorded an unprecedented progress in organ donation, allocation, and transplantation across the country.

As per the Health Ministry, about 18 per cent of transplants are currently being performed with the organs donated from deceased donors.

In 2025 alone, more than 1,200 families came forward to donate organs of their loved ones after death. Each donor is now also a multiorgan donor, transforming the lives of many.

Since September 2023, more than 4.8 lakh citizens have registered to donate organs and tissues after death through an Aadhaar-based verification system.

Notably, India has also achieved competence in performing difficult organ transplants like the heart, lungs, and pancreas.

The country also leads the world in hand transplants and performs a greater number of hand transplants than any other country.

Women, young ones and ones holding their babies, along with some men lined up on the outskirts of Zimbabwe's capital Harare for the injections of a new HIV prevention drug. The country launched it on Thursday. This drug needs to be administered only twice a year.

Why Is This Vaccine So Important For Zimbabwe?

Zimbabwe is a country where HIV led to tens of thousands of deaths in the last two decades. It is the first country to roll out lenacapavir, which is a long-acting drug that authorities have put their hopes on to slow down the HIV infection.

Also Read: Hangover Star Ken Jeong's Wife Beats Stage 3 Breast Cancer

What Is So Special About The HIV Injections?

Clinical studies have demonstrated near-total protection for the drug and has been described as a 'turning point' for high risk groups by many experts. However, many have warned that its broad impact would require overcoming funding constraints, infrastructure gaps and the challenge of keeping patients engaged.

Immunologist at Emory University Rama Rao Amara, calls it a "wonder drug". The drug, known as lenacapavir has been approved by the Food and Drug Administration (FDA) and is made by Gilead Sciences.

How Does This Drug Differ From Earlier HIV Prevention Drugs?

In 2021, FDA approved injectable form of PrEP medication called cabotegravir, however, this required patients to take it in every two months. This was also an intramuscular dose that healthcare providers were to administer into the buttocks.

What changes with lenacapavir is its easy administration. Each dose lasts longer compared to other medications and requires to be administered twice a year.

Read: 12.4 Lakh HIV Tests In Haryana Detect 5,877 Cases

The limitation with lenacapavir is its price tag of more than $28,000 per person per year. Carmen Pérez Casas, a senior strategy leader at Unitaid, a global health initiative based in Geneva, Switzerland said, "This is unaffordable. We need to get somewhere close to what previous options cost."

However, there is hope as the researchers published an analysis in The Lancet HIV that suggested generic versions of this drug could cost a person $25 per year.

Could This Drug Reshape HIV Prevention?

At the Zimbabwe launch, Constance Mukoloka, a sex worker, was among the first beneficiaries of this roll out which has happened by donor-support across 10 African countries, as reported by PBS News.

"I am safe, I can work with confidence now," said the 27-year-old sex worker. "When I took tablets, customers would see a container of pills and leave. They would never return due to fear," she said. "They couldn't tell the difference between PrEP and treatment drugs. With the work we do, that stigma costs you money."

Daily oral PrEP has been offered in Zimbabwe for years, along with condoms, vaginal rings and shorter-acting injections. However, sticking to the regimen has been difficult, especially for people dealing with stigma or irregular daily routines.

"I work in beer halls looking for clients. Sometimes I would get drunk and forget to take my drugs," Mukoloka said. "Sometimes I would work all night and not have time. Some clients refuse protection. They say ... 'Why should I use protection when I have paid?'"